BioSupply Trends Quarterly logo
Search
Close this search box.
Fall 2022 - Innovation

New Program Launched to Identify Autoimmune Disease Therapies

A cross-disciplinary coalition of experts from academic centers across the United States is partnering with the National Institutes of Health (NIH), the U.S. Food and Drug Administration, pharmaceutical companies and nonprofit organizations to identify new targets for therapies for autoimmune-meditated diseases.

A cross-disciplinary coalition of experts from academic centers across the United States is partnering with the National Institutes of Health (NIH), the U.S. Food and Drug Administration, pharmaceutical companies and nonprofit organizations to identify new targets for therapies for autoimmune-meditated diseases. The program, the Accelerating Medicine Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM), launched in December 2021, is sponsored by NIH and supported by $58 million in public and private funding. The purpose of the initiative, according to NIH, is to “deepen our understanding of the cellular and molecular interactions that lead to inflammation and autoimmune disease.”

AMP AIM is an expansion of a program launched in 2014 that focused on cellular and molecular pathways in rheumatoid arthritis (RA) and systemic lupus erythematosus. The expanded program will investigate psoriasis, psoriatic arthritis and Sjögren’s syndrome, in addition to RA and lupus.

References

Hurt, A. NIH Expands Autoimmune Research Program to Include More Rheumatic Diseases. Practical Pain Management, April 14, 2022. Accessed at www.practicalpainmanagement.com/news/nih-expands-autoimmune-research-program-to-include-more-rheumatic-diseases.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.